# Michael Werner

Nangungunang mga yugto ng podcast
Nai-update:

Naftali Group closes on $810M acquisition of Fifth Avenue luxury apartment building

Prolific real estate developer Naftali Group has closed on its more than $800 million deal to purchase a luxury apartment building on Manhattan's Fifth Avenue, records show. Miki Naftali, chairman and CEO of the firm, which boasts large presences in New York and Miami, signed the documents finalizi…

Private Markets: Are we witnessing an inflection point?

In this episode, Haley Tam and Michael Werner, Co-Heads of UBS’ European Diversified Financials Research, discuss what they see as a critical junction for private equity. They explore the inner workings of the private market and why it may be at a turning point. *(This information is subject to a d…

Forests on Forests

For much of history, tree canopies were pretty much completely ignored by science. It was as if researchers said collectively, "It's just going to be empty up there, and we've got our hands full studying the trees down here! So why bother?" But then around the mid-1980s, a few ecologists around th…

Hot Topics in FDA Regulation: GLP-1s, LDTs, AI and More

In this episode of Holland & Knight's "The Eyes on Washington" podcast series, attorneys Rachel Gartner, Sara Klock, John Vaughan and Michael Werner discuss the evolving landscape of U.S. Food and Drug Administration (FDA) regulation throughout the early months of the Trump Administration. Key topi…

DEA Plants the Seed for Rescheduling Marijuana: What's Next?

In this episode of "The Eyes on Washington Podcast," Public Policy & Regulation attorneys Michael Werner, Sara Klock, Joshua Odintz and Ed Perlmutter discuss the proposed rule by the U.S. Drug Enforcement Administration (DEA) to movie marijuana from a Schedule I drug to a Schedule III drug under th…

Changes in FDA, Cannabis Policies and AI Developments

In the latest episode of Holland & Knight's Public Policy & Regulation Group "Eyes on Washington" podcast series, Healthcare & Life Sciences attorneys Michael Werner and Sara Klock examine pivotal shifts in U.S. Food and Drug Administration (FDA) regulations. This episode explores updates in three …

A Conversation on Cannabis: Are Challenges or Changes Coming?

This episode was originally released on September 25, 2023 | In this episode of the "Eyes on Washington" podcast series by Holland & Knight's Public Policy & Regulation Group, Healthcare and Life Sciences attorneys Michael Werner and Sara Klock discuss recent developments in marijuana, particularly…

A Post-Election Checkup: FDA Policy and Regulation

This episode was originally released on December 21, 2022 | In this post-election special edition episode of Holland & Knight Public Policy & Regulation Group's "The Eyes on Washington" podcast series, healthcare attorneys Sara Klock and Michael Werner discuss how the elections will impact the U.S.…

The First 100 Days of the Biden Administration: COVID-19 Vaccines and HHS Updates

This episode was originally released on April 22, 2021 | In the fourth episode of Holland & Knight Public Policy & Regulation Group's "The First 100 Days of the Biden Administration" podcast series, Co-Leader of Holland & Knight's Healthcare & Life Sciences Team Michael Werner and Senior Public Aff…

He Beat Cancer And Says Most Owners Are Selling For The Wrong Reasons | Michael Werner

🚀 FREEDOM 2026 Get your Tickets Today! https://freedomevent.com Michael Werner has lived several business lifetimes: Goldman Sachs M&A, president of Werner Ladder at $500 million plus, the Gerber turnaround from $100 million to $700 million, and founder of HomeX, where he sold Schedule Engine to S…